Table 1.
Patient characteristics (full analysis set)
| Placebo (n = 195) | Duloxetine (n = 191) | p Value | |
|---|---|---|---|
| Age, yr | 49.5 ± 11.7 | 47.8 ± 12.0 | 0.1373a |
| Females | 164 (84.1) | 157 (82.2) | 0.6837 |
| Weight, kg | 56.28 ± 10.47 | 58.00 ± 11.23 | 0.1219a |
| Height, cm | 159.61 ± 7.76 | 159.41 ± 7.40 | 0.7922 |
| Major depressive disorder diagnosis | 7 (3.6) | 8 (4.2) | 0.7980 |
| Duration of fibromyalgia, yr | 5.7 ± 6.6 | 5.5 ± 5.9 | 0.6968 |
| Number of tender points | 15.5 ± 2.3 | 15.4 ± 2.3 | 0.8740 |
| BPI average pain score (0–10) | 6.13 ± 1.35 | 6.05 ± 1.29 | 0.5456 |
| FIQ total score (0–100) | 56.82 ± 16.14 | 55.95 ± 16.25 | 0.5950 |
| BDI-II total score (0–63) | 14.89 ± 9.62 | 15.34 ± 9.73 | 0.6533 |
BDI-II Beck Depression Inventory II, BPI Brief Pain Inventory, FIQ Fibromyalgia Impact Questionnaire
Values are means ± standard deviation or n (%). Continuous variables were analyzed using Welch’s t test, and categorical variables were analyzed using Fisher’s exact test
aStatistically significant at a two-sided significance level of 0.15